RBC cells represent a promising strategy to target therapeutic agent specific using biomimetic NPs with important application in cancer therapy due to their long time of circulation in vivo, to the presence of CD47 which allows to avoid phagocytosis from the immune system, for their semi-permeable membrane that allows a controlled sustained release. This evidence concerns the gene CD47 and cancer.